Amicus Therapeutics, Inc. (FOLD) Stock

FOLD logo

Amicus Therapeutics, Inc.

FOLD
Healthcare

Company profile

Amicus Therapeutics reported revenue of $634.21 million for fiscal year 2025, up 20.0% from fiscal year 2024. Ex-U.S. was its largest region in fiscal year 2025, with 58% of revenue. Our analysis of its filings shows revenue growing from $399.36 million in fiscal year 2023 to $634.21 million in fiscal year 2025, 26.0% a year on average.

What stands out

  • It reported a net loss in each of its last 5 fiscal years; the loss narrowed from $56.11 million in fiscal year 2024 to $27.11 million in fiscal year 2025.
  • It spent $135.84 million on research and development in fiscal year 2025, 21.4% of its revenue.
  • Revenue in fiscal year 2025 was the highest of the last 5 fiscal years.

Figures from company filings; latest fiscal year ended December 31, 2025.

Largest shareholders

  • Vanguard Fiduciary Trust Co.9.57%
  • Wellington Trust Co., NA9.48%
  • BlackRock Advisors LLC8.29%
  • Avoro Capital Advisor LLC5.86%
  • William Blair Investment Management LLC4.77%

Share of the company, as of November 8, 2025

How much revenue does Amicus Therapeutics make?

Amicus Therapeutics reported $634.21 million in revenue for fiscal year 2025, up 20.0% from $528.30 million in fiscal year 2024.

Where does Amicus Therapeutics make most of its revenue?

Ex-U.S.: 58% of revenue by region in fiscal year 2025, followed by United States (42%).

What companies are similar to Amicus Therapeutics?

Listed companies of a similar size in the same industry (metabolic process treatment drugs) include BioMarin Pharmaceutical Inc. (BMRN), Disc Medicine, Inc. (IRON), NewAmsterdam Pharma Company N.v. (NAMS), Maze Therapeutics, Inc. (MAZE).

Has Amicus Therapeutics made a profit in recent years?

Net income by fiscal year: FY2021, a loss of $250.46 million; FY2022, a loss of $236.57 million; FY2023, a loss of $151.58 million; FY2024, a loss of $56.11 million; FY2025, a loss of $27.11 million. It reported a net loss in each of these 5 years.

How has Amicus Therapeutics' revenue changed over the last 5 fiscal years?

Revenue by fiscal year: FY2021, $305.51 million; FY2022, $329.23 million; FY2023, $399.36 million; FY2024, $528.30 million; FY2025, $634.21 million.

Company Information

SectorHealthcare
IndustryMetabolic Process Treatment Drugs
Founded2002
IPO DateMay 31, 2007
IPO StatusPublic
FoundersJohn Crowley
ExchangeNasdaqGM
TimezoneAmerica/New_York (EST)
Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.

Data as of .

How to cite: DataPorium, “Amicus Therapeutics, Inc. (FOLD)”, data as of Dec 31, 2025, https://dataporium.tech/stocks/FOLD

LinkedInLinkedInXXYouTubeYouTube